clinical research

The Oncomine Acute Myeloid Leukaemia (AML) Panel is a cutting-edge genetic test that provides a full genomic picture of AML, helping doctors pinpoint key mutations, gene fusions, and copy number changes in genes known to drive the disease. Using advanced next-generation sequencing (NGS), this test delivers fast, precise results, even from limited or degraded sample, so patients get an accurate diagnosis and tailored treatment plans sooner.